This paper is only available as a PDF. To read, Please Download here.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Value in HealthAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
Accepted:
January 15,
2023
Received:
January 11,
2023
Publication stage
In Press Accepted ManuscriptFootnotes
Many argue that drug prices should better reflect investments for research and development, while guaranteeing a reasonable return on investment. Although this approach might seem fair, it raises several issues.
Author Contributions:
Concept and design: Annemans
Acquisition and date: Annemans
Drafting of the manuscript: Annemans
Analysis and interpretation of data: Annemans
Conflict of Interest Disclosures:
The author reported no conflicts of interest.
Funding/Support: The author received no financial support for this research.
Identification
Copyright
© 2023 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.
